Mifepristone-d3
(Synonyms: RU486-d3; RU 38486-d3) 目录号 : GC47674A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Mifepristone-d3 is intended for use as an internal standard for the quantification of mifepristone by GC- or LC-MS. Mifepristone is an antagonist of glucocorticoid, progesterone, and androgen receptors (Kis = 0.1, 0.64, and 0.65 nM, respectively).1,2,3 It is selective for these receptors over the mineralocorticoid receptor (MR), estrogen receptor α (ERα), and ERβ (Kis = 640, >200, and >750 nM, respectively).1 In cell-based assays, mifepristone inhibits alkaline phosphatase activity stimulated by the progesterone receptor agonist R5020 as well as reporter transcription stimulated by either dexamethasone or R5020 (IC50s = 7, 5.9, and 1.3 nM, respectively).3 It also inhibits synthetic androgen R1881-stimulated reporter transcription in a concentration-dependent manner.2 Mifepristone (10 µM) inhibits growth of 4-OHT-resistant MCF-7 breast cancer cells in vitro.4 It also inhibits tumor growth in an SKOV3 ovarian cancer nude mouse xenograft model when administered at doses of 0.5 or 1 mg per day.5 Formulations containing mifepristone have been used for the induction of medical abortions.
1.von Gerldern, T.W., Tu, N., Kym, P.R., et al.Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetesJ. Med. Chem.47(17)4213-4230(2004) 2.Song, L.-N., Coghlan, M.J., and Gelmann, E.P.Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptorMol. Endocrinol.18(1)70-85(2004) 3.Attardi, B.J., Burgenson, J., Hild, S.A., et al.In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristoneJ. Steroid Biochem. Mol. Biol.88(3)277-288(2004) 4.Gaddy, V.T., Barrett, J.T., Delk, J.N., et al.Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cellsClinical Cancer Research105215-5225(2004) 5.Goyeneche, A.A., CarÓn, R.W., and Telleria, C.M.Mifepristone inhibits ovarian cancer cell growth in vitro and in vivoClin. Cancer Res.13(11)3370-3379(2007)
Cas No. | N/A | SDF | |
别名 | RU486-d3; RU 38486-d3 | ||
Canonical SMILES | O=C1CCC(C(CC2)=C1)=C([C@]2([H])[C@@](CC[C@]3(C#CC)O)([H])[C@]3(C)C4)[C@H]4C5=CC=C(N(C([2H])([2H])[2H])C)C=C5 | ||
分子式 | C29H32D3NO2 | 分子量 | 432.6 |
溶解度 | Chloroform: Soluble,Methanol: Soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3116 mL | 11.558 mL | 23.116 mL |
5 mM | 0.4623 mL | 2.3116 mL | 4.6232 mL |
10 mM | 0.2312 mL | 1.1558 mL | 2.3116 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。